Clinical trials: Intravenous Therapy
Anaemia
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
The purpose of this study is to look at how well Ferric Carboxymaltose, an intravenous iron therapy (iron that is infused directly into your body through a vein), compares with ferrous sulphate capsules taken by mouth in the…
- Trial name
- ASAP (NCT01131624)
- Testing
- ferrous sulphate, Ferinject
- Where
- 20 sites in Australia, Germany and 3 more
- Volunteers
- 252 people
- Sponsor
- Vifor Pharma
Ileus
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
This study will evaluate the safety and efficacy of two different dose regimens (12 milligrams [mg] and 24 mg) of IV MOA-728 versus placebo in shortening the time to return of bowel function in participants receiving opioid…
- Trial name
- NCT00528970
- Testing
- MOA-728
- Where
- 106 sites in United States, Australia and 9 more
- Volunteers
- 374 people
- Sponsor
- Bausch Health Americas, Inc.
Duchenne Muscular Dystrophy
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain.
- Trial name
- NCT05693142
- Testing
- RGX-202
- Where
- 23 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- REGENXBIO Inc.
Cryptosporidiosis, HIV Infections
Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs
To provide azithromycin for the treatment of individual patients with proven cryptosporidiosis whose disease has persisted or progressed despite prior therapies.
- Trial name
- NCT00002328
- Testing
- Azithromycin
- Where
- United States
- Sponsor
- Pfizer
Crohn's Disease
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Protocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body…
- Trial name
- NCT00482092
- Testing
- Prochymal®
- Where
- 56 sites in United States, Australia and 2 more
- Volunteers
- 330 people
- Sponsor
- Mesoblast, Inc.
Intensive Care Unit, Coronary Artery Bypass Grafting (CABG)
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight…
- Conditions
- Intensive Care Unit, Coronary Artery Bypass Grafting (CABG), High Risk Patients, Cardiopulmonary Bypass
- Trial name
- MODIFY CSX (NCT06279793)
- Testing
- Fish Oil, Intravenous 0.9% Sodium Chloride
- Where
- 10 sites in Germany
- Volunteers
- 550 people
- Sponsor
- GCP-Service International West GmbH
Infiltration of Peripheral IV Therapy
Optical Detection of Intravenous Infiltration:A Pilot Study
This study will examine the use of the ivWatch Model 400 to monitor PIV sites in pediatric patients. Half the participants will be monitored by the device without infiltration notifications and the other half will be monitored by…
- Trial name
- NCT02553421
- Testing
- ivWatch Model 400
- Where
- United States
- Volunteers
- 243 people
- Sponsor
- ivWatch, LLC
SMA - Spinal Muscular Atrophy, Gene Therapy
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
- Trial name
- STR1VE (NCT03306277)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 16 sites in United States
- Volunteers
- 22 people
- Sponsor
- Novartis Gene Therapies
Peptic Ulcer Hemorrhage
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
The purpose of this phase study is to confirm the efficacy and safety by compare ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding.
- Trial name
- NCT03362281
- Testing
- Ilaprazole, Omeprazole, Ilaprazole tablet
- Volunteers
- 540 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Alzheimer´s Disease
Phase 3 IGIV, 10% in Alzheimer´s Disease
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
- Trial name
- NCT01524887
- Testing
- Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
- Where
- 69 sites in United States, Australia and 6 more
- Volunteers
- 508 people
- Sponsor
- Baxalta now part of Shire
Stroke, Acute, Middle Cerebral Artery Stroke
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
The primary objective of the study is to assess the safety and tolerability of Human Placenta-Derived Cells (PDA001) at 3 different dose levels versus placebo (vehicle control) administered intravenously in subjects following…
- Conditions
- Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke
- Trial name
- NCT01310114
- Testing
- Human Placenta-Derived Cells PDA001- (cenplacel-L)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Celularity Incorporated
Cancer
The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer
The purpose of this study is to compare the pharmacokinetic and safety characteristics of European Taxotere® and American Taxotere® with Hospira Docetaxel injection in patients with cancer.
- Trial name
- NCT01268163
- Testing
- European Taxotere®, American Taxotere®, Hospira Docetaxel Injection
- Where
- 4 sites in Russia, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory…
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05020678
- Testing
- NKX019
- Where
- 6 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Nkarta, Inc.
Gram-negative Bacterial Infection
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria.
- Trial name
- CHERISH (NCT06462235)
- Testing
- Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4
- Where
- 32 sites in United States, Argentina and 7 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Melanoma
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration.
- Trial name
- NCT06101134
- Testing
- relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab
- Where
- 31 sites in United States, Chile and 3 more
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Breast Neoplasms
EPO906 Therapy in Patients With Advanced Breast Cancer
This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause breast cancer.
- Trial name
- NCT00035126
- Testing
- epothilone b
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Precursor Cell Lymphoblastic Leukemia-lymphoma
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with…
- Trial name
- NCT03888534
- Testing
- Ixazomib
- Where
- 7 sites in United States, Spain
- Sponsor
- Millennium Pharmaceuticals, Inc.
Male Osteoporosis
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
- Trial name
- NCT00439647
- Testing
- Zoledronic acid 5 mg iv
- Where
- 128 sites in Argentina, Australia and 21 more
- Volunteers
- 1,199 people
- Sponsor
- Novartis Pharmaceuticals
Infection
Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.
- Trial name
- NCT00492726
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Ertapenem intravenous
- Where
- 52 sites in Argentina, Belgium and 12 more
- Volunteers
- 804 people
- Sponsor
- Bayer
Thyroid Eye Disease
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.
- Trial name
- NCT06389578
- Testing
- Teprotumumab
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Amgen